Drug intelligence / Profile preview

Bis98

Development stage: Preclinical
Lead developer: L&L Biopharma
Modality: Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

Bis98 is a preclinical-stage trispecific antibody being developed by L&L Biopharma. It is specifically engineered to address cancers that have developed resistance to anti-PD-1 therapies. While the specific molecular targets of the antibody have not been publicly disclosed by the developer, the molecule is designed to engage multiple pathways simultaneously to overcome immune checkpoint inhibitor resistance and enhance anti-tumor immune responses. Bis98 is part of L&L Biopharma's broader pipeline of multi-specific biologics aimed at treating refractory solid tumors.

Beyond the preview

Go deeper on Bis98.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bis98.

Explore the full profile